Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR-TKI treatment-Reference-Cited by-同舟云学术

Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR-TKI treatment

Published:2016-12-20 Issue:1 Volume:7 Page:35-43
ISSN:2211-5463
Container-title:FEBS Open Bio
language:en
Short-container-title:FEBS Open Bio

Author:

Cao Haixia¹,Yu Shaorong¹²,Chen Dan¹,Jing Changwen¹,Wang Zhuo¹,Ma Rong¹,Liu Siwen¹,Ni Jie³,Feng Jifeng¹²,Wu Jianzhong¹

Affiliation:

1. Research Center for Clinical Oncology; Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research; Nanjing Medical University Affiliated Cancer Hospital; Jiangsu Province China

2. Department of Oncology; Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research; Nanjing Medical University Affiliated Cancer Hospital; Jiangsu Province China

3. The Fourth Clinical School of Nanjing Medical University; Jiangsu Province China

Funder

National Natural Science Foundation of China

Natural Science Foundation of Jiangsu Province

Publisher

Wiley

Subject

General Biochemistry, Genetics and Molecular Biology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/2211-5463.12147/fullpdf

Reference29 articles.

1. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009